1古家大裙,四方贤一.糖尿病肾病N危险因子.Diab etes and Kidney Disease.Timetoact(日本语翻译版),2003,1(1):17-25.33-39. 被引量：1
2Fried LF, Du ckw orth W, Zhang JH, et al. Design of combinatio- nangiotens in receptor blocker and angiotens in - converting en- zyme inhibitor for treatment of diabetic nephropathy (VA- NEPHRON - D). Clinical Journal of The American Society of Nephrelogy,2009,4(2) :361 - 368. 被引量：1
3Thilly N, Bayat S, Alia F, et al. Determinants and patterns of ren- inangiotens in system inhibitor spprescription in the first year fol- low ingkidney transplantation. Clinical Transplantation, 2008,22 (4) :439 -446. 被引量：1
4Wang G, Lai FM, Lai KB, et al. Urinary mRNA expression of ACE and ACE 2 in human type 2 diabetic nephropathy. Diabeto- logia, 2008,51 ( 6 ) : 1062 - 1067. 被引量：1
9Garber AJ.Ineretin-based therapics in the management of type 2diabetes;rationale and reality in a managed care setting[J].Am J Manag Care,2010,16(suppl 7):S187-S194. 被引量：1
10Fried LF,Duckworth W,Zhang JH,et al.Design of combination angiotens in recep tor blocker and angiotensin 2converting enzyme in 2hibitor for treatment of diabetic nephropathy(VANEPHRON 2D)[J].Clinical Journal of The American Society of Nephrology,2009,4(2):361-368. 被引量：1
8Lizicarova D, Krahulec B, Hirnerova E, et al. Risk factors in diabetic nephropathy progression at present [J]. Bratisl Lek Listy, 2014, 115(8): 517-521. 被引量：1
9Kowalski A, Krikorian A, Lerma EV. Diabetic nephropathy forthe primary care provider: new understandings on early detection and treatment [J]. Ochsner J, 2014, 14(3): 369-379. 被引量：1
10Zhang H, Cai X, Yi B, et al. Correlation of CTGF gene promoter methylation with CTGF expression in type 2 diabetes mellitus with or without nephropathy[J]. Mol Med Rep, 2014, 9(6):2138-2144. DOI: 10.3892/mmr.2014.2067. 被引量：1
